Tema’s Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Tags

12/02/2025 - 06:00 AM

NEW YORK--(BUSINESS WIRE)-- Tema ETFs (“Tema”), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (“CANC”) has surpassed $100m in assets under management (AUM) two years since launch. The CANC ETF invests in leading oncology companies and cancer therapies and is the only pure-play oncology focused ETF in the world, managed by Dr. David Song MD, PhD, CFA.¹

Key Highlights of the Tema Oncology ETF (CANC):

1. Rising Oncology Need

Cancer is the leading cause of death under the age of 85 according to a January 2025 study by the American Cancer Society, with a notable rise in prevalence amongst women and younger men. In some countries like the UK, the lifetime risk of cancer is now more than 50% in people born since 1960 according to the British Medical Journal (BMJ).¹

2. Standout 2025 Performance

CANC is up +48.0% year-to-date, compared with +15.7% for the S&P 500 index. Based on Bloomberg’s defined universe of 47 healthcare and biotechnology ETFs, that return places CANC among the top 3 best-performing healthcare and biotechnology ETFs this year.²

3. Distinguished Healthcare Investing Expertise

CANC is managed by Dr. David Song MD, PhD, CFA. Dr. Song originally studied medicine at the University of Pennsylvania, before beginning a healthcare investing career that has spanned more than two decades at firms including Rockefeller Capital, Balyasny and Millennium.

“Cancer remains one of the world’s deadliest diseases, making oncology among the largest and fastest-growing areas of innovation within healthcare. Yet investing in this space can be inherently complex and risky. We designed CANC to harness my experience and provide investors access to companies at the forefront of the fight against cancer—many of which are overlooked by conventional indexes.” said Dr. David Song, Portfolio Manager for the Tema Oncology ETF.

About Tema ETFs

Tema ETFs is an active ETF investment manager founded in 2023 to empower investors with durable and strategic portfolio solutions spanning quality, core, thematics and alternatives. Tema is backed by Index Ventures, Accel Partners and over a dozen financials services CEOs and fintech founders.

For more information, visit www.temaetfs.com

Footnotes

¹ Note: all market and fund data are as of 26-Nov-2025 from Bloomberg. The American Cancer Society Report can be accessed at https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21871, the British Medical Journal report can be accessed at https://www.bmj.com/content/350/bmj.h614. The pure-play qualification is premised on that CANC is only ETF globally with Oncology in the name.

² Note: The Bloomberg universe of healthcare and biotechnology ETFs includes ALPS Medical Breakthroughs ETF, Virtus LifeSci Biotech Product ETF, Simplify Propel Opportunities ETF, Harbor Health Care ETF, Horizon Kinetics Medical ETF, Virtus LifeSci Biotech Clinical ETF, Invesco Nasdaq Biotechnology ETF, Invesco Pharmaceuticals ETF, SPDR S&P Health Care Services ETF, SPDR S&P Pharmaceuticals ETF, Roundhill GLP-1 & Weight Loss ETF, iShares U.S. Pharmaceuticals ETF, Global X Aging Population ETF, SPDR S&P Biotech ETF, Fidelity Digital Health ETF, iShares Biotechnology ETF, Global X HealthTech ETF, First Trust NYSE Arca Biotechnology ETF, iShares Health Innovation ETF, Simplify Health Care ETF, ROBO Global R Healthcare Technology ETF, Tema Heart & Health ETF, First Trust Nasdaq Pharmaceuticals ETF, VanEck Pharmaceutical ETF, First Trust Health Care ETF, Invesco Biotechnology & Genomics ETF, VanEck Biotech ETF, iShares Neuroscience And Health ETF, iShares Genomics Immunology ETF, iShares Global Healthcare ETF, Amplify Weight Loss Drug & Treatments ETF, JPMorgan Healthcare Leaders ETF, Vanguard Health Care ETF, Fidelity MSCI Health Care Index ETF, iShares U.S. Healthcare Providers ETF, iShares U.S. Medical Devices ETF, Health Care Select Sector SPDR ETF, iShares U.S. Healthcare ETF, Fidelity Disruptive Medicine ETF, Putnam BioRevolution ETF, Invesco S&P 500 Equal Weight Healthcare ETF, Global X Genomics & Biotechnolgy ETF, Langar Global Healthtech ETF, Goldman Sachs Future Health Care ETF, First Trust Indxx Medical Devices ETF, Invesco S&P SmallCap Health ETF, SPDR S&P Health Care Equipment ETF.

* The S&P Biotechnology Select Industry Index (XBI) is a modified equal-weighted index representing the U.S. biotechnology sub-industry of the S&P Total Market Index. It tracks a wide range of U.S. listed biotechnology companies, including small-, mid-, and large-cap firms, engaged in research, development, and commercialization of biotechnology products

Disclosures

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com. Read the prospectus carefully before investing.

Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.

Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.

Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.

Oncology Companies Risk: Oncology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company's valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable.

The stock prices of oncology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable. Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained.

An investment cannot be made directly into an index.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. For performance data current to the most recent month-end, visit https://temaetfs.com/canc.

Investing in Foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.

Because the Fund evaluates ESG factors to assess and exclude certain investments for non-financial reasons, the Fund may forego some market opportunities available to funds that do not use these ESG factors.

Tema ETFs LLC serves as the investment adviser to Tema Oncology ETF (the “Fund”), and NEOS Investments, LLC serves as a sub-adviser to the Fund. The Fund is distributed by Foreside Fund Services LLC, which is not affiliated with Tema ETFs LLC nor NEOS Investments, LLC. Check the background of Foreside on FINRA’s BrokerCheck.